Logo for Kymera Therapeutics Inc

Kymera Therapeutics Investor Relations Material

Latest events

Logo for Kymera Therapeutics Inc

Q4 2023

Kymera Therapeutics
Logo for Kymera Therapeutics

Q4 2023

22 Feb, 2024
Logo for Kymera Therapeutics

Corporate Presentation

5 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Kymera Therapeutics Inc

Access all reports
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. These targeted intracellular proteolytic inhibitors are designed to slow or stop the progression of a variety of serious diseases including cancer and cystic fibrosis. The Company has some marketed products, for example defactinib (Ribomunex), which is approved for the treatment of adults with cystic fibrosis that have a certain genetic mutation; and TRU-016 (Refacto AF) for the treatment of adults with pancreatic ductal adenocarcinoma (PDAC) who have received previous chemotherapy containing gemcitabine and/or erlotinib.